ArticleFrontiers in cellular and infection microbiology2025
Antimicrobial activity and mechanistic insights of AMP-17 against drug-resistant
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chronic wound infections caused by drug-resistant bacteria have emerged as a global health challenge, affecting millions of patients annually and imposing a substantial economic and societal burden. However, current therapeutic approaches exhibit limited efficacy in treating drug-resistant wound infections, highlighting an urgent need for novel treatment strategies. Our previous studies have demonstrated that the Materials and methods: MIC/MBC of AMP-17 against drug-resistant Results and discussion: The results of this study demonstrate that AMP-17 exhibits significant antimicrobial activity against drug-resistant Pseudomonas aeruginosa. The underlying mechanisms primarily involve disruption of bacterial membrane integrity, alteration of proton motive force (PMF), increased intracellular ROS levels, and inhibition of bacterial motility, ultimately leading to bacterial cell death. Additionally, AMP-17 shows promising efficacy in inhibiting biofilm formation and eradicating mature biofilms of drug-resistant
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.